A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets.

Wang L, Jung J, Babikir H, Shamardani K, Jain S, Feng X, Gupta N, Rosi S, Chang S, Raleigh D, Solomon D, Phillips JJ, Diaz AA. · 2022

Read A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets. by Wang L, Jung J, Babikir H, Shamardani K, Jain S, Feng X, Gupta N, Rosi S, Chang S, Raleigh D, Solomon D, Phillips JJ, Diaz AA. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9767870.txt.

Introduction

Wang and co-authors chart how glioblastoma changes under therapy in a paired single-cell atlas. The brain tumor resists every standard treatment tried so far. Recurrent tumors show little new mutation pressure at relapse. That hints cells escape by switching states, not genes.

The team profiled 86 matched pairs of first and recurrent tumors. RNA, chromatin, DNA, and spatial assays all fed the atlas. Recurrent tumors had shifted toward a mesenchymal cell state. A factor group called AP1 drove that state change. More T cells at relapse linked to better outlooks. That tie also matched tumors with high mutation loads. Signal webs between tumor, glial, and immune cells emerged. Those webs point to targets inside and outside tumor cells. The atlas is offered as a base for new therapy design.

Catalog record

CREATORWang L, Jung J, Babikir H, Shamardani K, Jain S, Feng X, Gupta N, Rosi S, Chang S, Raleigh D, Solomon D, Phillips JJ, Diaz AA.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE85 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9767870

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets By Lin Wang, Jangham Jung, Husam Babikir, Karin Shamardani, Saket Jain, Xi Feng, Nalin Gupta, Susanna Rosi, Susan Chang, David Raleigh, David Solomon, Joanna J. Phillips Published in: Nature Cancer DOI: 10.1038/s43018-022-00475-x ABSTRACT Recent longitudinal studies of glioblastoma (GBM) have demonstrated a lack of apparent selection pressure for specific DNA mutations in recurrent disease. Single-cell lineage tracing has shown that GBM cells possess a high degree of plasticity. Together this suggests that phenotype switching, as opposed to genetic evolution, may be the escape mechanism that explains the failure of precision therapies to date. We profiled 86 primary-recurrent patient-matched paired GBM specimens with single-nucleus RNA, single-cell open-chromatin, DNA and spatial transcriptomic/proteomic assays. We found that recurrent GBMs are characterized by a shift to a mesenchymal phenotype. We show that the mesenchymal state is mediated by activator protein 1. Increased T-cell abundance at recurrence was prognostic and correlated with hypermutation status. We identified tumor-supportive networks of paracrine and autocrine signals between GBM cells, nonmalignant neuroglia and immune cells. We present cell-intrinsic and cell-extrinsic targets and a single-cell multiomics atlas of GBM under therapy. MAIN The genetics of glioblastoma (GBM), the most common and aggressive primary malignancy of the adult brain, have been extensively characterized1–3. Despite this fact, GBMs have proven resistant to all genotoxic therapies employed in clinical trials thus far. Recent longitudinal studies of GBMs based on bulk DNA sequencing demonstrate a lack of selection pressure for DNA mutations that are private to either primary or recurrent disease, a lack of association between genetic selection pressure and standard therapy and a remarkable clonal stability under therapy4. These findings are consistent with recent molecular analyses of spatially mapped biopsies from GBM specimens, which find minimal evidence of intra-tumor regional heterogeneity in clonal mutations5. Taken together, these results support the hypothesis that selection pressure for or against specific mutations occurs mostly during initial malignant transformation and that standard chemoradiation therapy does not apply significant additional selection pressure at the level of genomic alteration. On the other hand, recent single-cell/single-nucleus RNA-sequencing (sc/snRNA-seq) studies of primary disease have demonstrated that GBM cells exhibit a high degree of plasticity at the phenotypic level and apparent transitions between cellular states6–9; however, it is unknown to what extent standard therapy, temozolomide (TMZ) chemotherapy, ionizing radiation (IR) and surgical resection, applies a selection pressure for or against specific cell types at recurrence. The extent to which standard therapy shapes the milieu of tumor-associated immune cells and nonmalignant neuroglia is not fully understood. To address this, we performed snRNA-seq on a cohort of patient-matched primary-recurrent paired specimens (n = 86), together with single-cell assay for transposase-accessible chromatin via sequencing (scATAC-seq), spatial transcriptomics (ST), spatial proteomics (SP) and exome sequencing (exome-seq) for specific subcohorts (Fig. 1a). We present a single-cell multi-omics atlas of GBM under therapy. This resource fills a gap in our knowledge of GBM at recurrence and has allowed us to derive several clinically relevant findings.Fig. 1A single-cell RNA atlas of human glioblastoma through recurrence.a, An overview of genomics studies on paired longitudinal GBM specimens. b, A t-distributed stochastic neighbor embedding (t-SNE) of the first ten principal components of snRNA-seq data. Cells with CNVs are annotated. n = 86 tumors were used (b–d). c, A hierarchical clustering of cells without CNVs, with several cluster-specific genes highlighted. d, A summary of sample cellular composition, genotype and demographics. Top: cellular composition inferred from snRNA-seq. Middle: patient and sample annotations, with genotype inferred from snRNA-seq. Bottom: genotypes inferred from the UCSF500 clinical DNA-amplicon-sequencing assay performed on adjacent tissue and controlled by sequencing a patient-matched blood specimen. We extend our previous finding that proliferating GBM cells lie on a single axis of variation, ranging from the Verhaak proneural (PN) to mesenchymal (MES) phenotypes to the context of recurrent GBM. On average, we found that GBM patients undergo a PN-to-MES shift at recurrence, concomitant with an increase in the birth rate of MES cells in recurrent tumors and supported by paracrine signals from the tumor microenvironment. We identified gene-expression correlates of the re-entry of previously quiescent MES cells into the cell cycle at recurrence and found that targeting these genes decreases GBM cell viability. We identified chromosome-arm-scale copy-number variants (CNVs) that correlate with the MES phenotype, not previously described. Hypermutation status was found to be a predictor of increased T-cell infiltration at recurrence. Moreover, increased T-cell infiltration at recurrence was prognostic. Last, we mapped intercellular paracrine and autocrine signals between neoplastic cells, non-neoplastic neuroglia and immune cells via snRNA-seq. We validated coexpression of these signals in situ via ST and SP. We showed that these signals enhance GBM cell viability in a panel of low-passage patient-derived cell lines and are targetable therapeutically. Taken together, these studies address fundamental questions of GBM cellular biology and the selection pressure applied by standard therapy, as well as provide therapeutic targets for further development. RESULTS Single-cell transcriptomics of longitudinal GBM specimens We profiled 86 longitudinal fresh-frozen tissue specimens from 49 patients undergoing surgical resection for GBM via snRNA-seq. For 36 patients we profiled paired specimens from the primary untreated tumor and matched first recurrence (Fig. 1a and Supplementary Table 1), additionally we profiled four untreated-primary and six first recurrence unmatched specimens. At the time of the first recurrence all patients had been treated only with standard-of-care therapy (TMZ, IR and surgical resection). The cohort’s age ranged from 35–76 years and had a male-to-female ratio of 1.2. Nuclei isolation from frozen tissue, nuclei capture and library preparation were performed as previously described8, yielding 254,288 transcriptomes. We found that data quality metrics for our single-nucleus data, such as number of features per cell (Extended Data Fig. 1a) or doublet rate (Extended Data Fig. 1b), met or exceeded the quality for recent GBM single-cell studies7,9. Neoplastic cells (daughters of the tumor-initiating cell) were separated from nonmalignant neuroglia, endothelial and immune cells via our previously described approaches10–12, which include an analysis of gene signatures as well as expressed mutations (Fig. 1b–d). Mutation profiles were validated by DNA-amplicon sequencing via the UCSF500 panel for 52 of 86 cases, the mutational status of isocitrate dehydrogenase (IDH) was assessed for all patients via sequencing and and/or immunohistochemistry. Four samples were identified as having mutations in IDH1 and were excluded from further analysis. We use the term GBM to refer to IDH-wild-type GBM from hereafter. On average, samples from recurrent tumors had less purity than primary cases (Fig. 1d and Extended Data Fig. 1c). All cell types found were represented in specimens from across all lobes of the brain, a spectrum of ages and both sexes (Extended Data Fig. 1d–g). Meta-analysis supports a proneural–mesenchymal axis We recently showed that the phenotypes of proliferating primary GBM cells have a dominant axis of variation that ranges from the MES to PN transcriptional subtypes8. Subsequent scRNA-seq studies of primary GBM specimens and patient-derived tumor-propagating cells have produced similar findings6. We performed a meta-analysis of snRNA-seq data from our primary tumors and other recent single-cell studies of primary GBMs7,9. An unbiased multiple-factor analysis (MFA; Methods), an extension of principal-component analysis (PCA) to multiple tables, showed that the largest contribution to variation in primary GBM neoplastic cells

Read the complete text